• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Rongmi,LU Qian,JIN Ming,HUANG Xiaofei,YU Qinwei,JIANG Zhenzhou.Research progress in the treatment of non-alcoholic fatty liver disease based on the long chain fatty acids and related metabolic enzymes[J].Journal Of Pharmaceutical Research,2024,43(12):1203-1211[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2711times   Download 1990次 QR Code for this article
Scan with your phone!
基于长链脂肪酸及相关代谢酶治疗非酒精性脂肪性肝病的研究进展
张荣觅1,陆茜1,金铭1,黄小菲1,俞沁玮1,江振洲1,2
Font:Larger+|Default|Smaller-
(1.中国药科大学,多靶标天然药物全国重点实验室,新药筛选与药效评价中心,江苏省药效研究与评价服务中心,江苏 南京 210009;2.中国药科大学,药物质量与安全预警教育部重点实验室,江苏 南京 210009)
摘要:
长链脂肪酸,即碳原子数大于12,小于等于20的脂肪酸,是膳食中含量最高的脂肪酸类别。长链脂肪酸参与维持细胞膜的正常结构和基本功能,在机体能量代谢、糖脂代谢及免疫炎症反应中都发挥着重要作用。而肝细胞中,长链脂肪酸超载可从诱导炎症、氧化应激、纤维化、自噬、细胞凋亡等多种途径诱导肝损伤。本文综述了基于长链脂肪酸及相关代谢酶治疗非酒精性脂肪性的研究进展,为非酒精性脂肪性肝病的治疗提供新的思路和方法。
关键词:  非酒精性脂肪性肝病  长链脂肪酸  脂肪酸代谢
DOI:10.13506/j.cnki.jpr.2024.12.012
基金项目:国家自然科学基金项目(No.82304642);江苏省自然科学基金面上项目(No.BK20221526);江苏省自然科学基金青年项目(No.BK20210430)
Publication Date:December 25, 2024
Research progress in the treatment of non-alcoholic fatty liver disease based on the long chain fatty acids and related metabolic enzymes
ZHANG Rongmi1,LU Qian1,JIN Ming1,HUANG Xiaofei1,YU Qinwei1,JIANG Zhenzhou1,2
(1.State Key Laboratory of Natural Medicines, Center for New Drug Safety Evaluation and Research, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009,China;2. Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Nanjing 210009,China)
Abstract:
Long-chain fatty acids(LCFA) are defined as fatty acids with 12-20 carbons. LCFA are the most abundant type of fatty acids in diet. LCFA are involved in maintaining the normal structure and basic function of cell membranes, which play an important role in energy metabolism of the organism, glucose and lipid metabolism, and inflammatory response. In hepatocytes, an overload of LCFA can induce liver injury in various ways such as inflammation, oxidative stress, fibrosis, autophagy, and apoptosis. This article reviews the research progress of treating non-alcoholic fatty disease based on long chain fatty acids and related metabolic enzymes, providing new ideas and strategies for the treatment of non-alcoholic fatty liver disease.
Key words:  Non-alcoholic fatty liver disease  Long chain fatty acid  Fatty acid metabolism
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.